Business Wire

Panasonic LUMIX GH5 Supports Yasunaga Ogita, a Polar Explorer, in Japan's First Solo South Pole Expedition Without Resupplies

Jaa

Panasonic Corporation supported Polar explorer Yasunaga Ogita, the first Japanese explorer to successfully reach the South Pole in a sole expedition on foot and without resupplies, by providing a LUMIX GH5 Camera, an equipment to record the journey in still and video images. Mr. Ogita is participating as a LUMIX ambassador.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180121005155/en/

The Polar explorer Yasunaga Ogita at the press conference, after accomplishing the solo South Pole e ...

The Polar explorer Yasunaga Ogita at the press conference, after accomplishing the solo South Pole expedition (Photo: Business Wire)

Mr. Ogita began the expedition on November 17, 2017, local time, and hiked for 1,126 kilometers to reach the South Pole 50 days later, on January 5, 2018. He was the first Japanese ever to reach the South Pole on foot and without receiving any backup supplies.

In addition to high-quality still image features such as the high-resolution 6K PHOTO function, the LUMIX GH5 offers professional-level 4K videos in a single, compact body. It is the flagship model of LUMIX's Digital Single Lens Mirrorless Cameras.

In order to record the expedition itself as well as the South Pole environment and eco-system, an digital camera for high-quality still images and videos was essential. In conventional North Pole expeditions, it was necessary to bundle a still camera, a video camera, batteries for each, and peripheral equipment onto a sled. Mr. Ogita's solo expedition without resupplies required him to pull a sled that weighed about 100 kilograms, which meant that any additional weight became a serious issue. The LUMIX GH5 was selected to solve the dual problem of high-quality recording and light weight. It provided excellent still images and videos in a single compact, lightweight camera. The GH5 was also able to withstand field shooting in temperatures down to minus 10ºC with its dust-proof, splash-proof(*1) and low-temperature(*2) design, further adding to the reasons for its selection.

Still images and videos from the South Pole expedition and Mr. Ogita's previous North Pole expeditions are posted on the LUMIX website.

Notes:
*1: With a Panasonic dust-proof, splash-proof lens mounted.
*2: With an optional Panasonic low-temperature design lens (H-ES12060, H-HSA12035, H-HSA35100)

Panasonic Equipment Supporting the Solo South Pole Expedition without Resupplies:
LUMIX GH5 (DC-GH5) ... 2 Cameras
Battery Grip (DMW-BGGH5) ... 1 piece
Batteries ... 5 pieces
Battery Charger ... 1 piece
Lens: 14-140mm (H-FS14140)
Lens: 12-60mm (H-ES12060)
LPL58 Filter

About Yasunaga Ogita
Yasunaga Ogita (Polar explorer)
Born September 1, 1977, in Aiko-Gun, Aikawa-Machi, Kanagawa.
Resides in Kamikawa-Gun, Takasu-Cho, Hokkaido.

Yasunaga Ogita conducts solo expeditions mainly in Canada and the Arctic Circle, Greenland, and the areas around the Arctic Ocean. He has taken 15 expeditions to the North Pole in 18 years from 2000 to 2017, in which he has traveled more than 9,000 km in the Arctic region. Having one of the world's leading Arctic adventure carriers, he draws attention from domestic and foreign media as Japan's only "Arctic adventurer."
He has also appeared in many documentaries, including "Crazy Journey" (TBS), "News Watch 9" (NHK), and "Nonfiction W" (WOWOW). In addition, he has been presented in a wide variety of other media, such as radio, magazines, and newspapers. During summer vacations in Japan, he has led groups of elementary school children on 160-km journeys in his "100 Mile Adventure" since 2012. During these journeys, he relays the experiences that he has had in the Arctic Circle.
Yasunaga Ogita meets regularly with researchers from the Japan Agency for Marine-Earth Science and Technology, the National Institute of Polar Research, and universities, with whom he often carries out joint research. He is active in many aspects of the Arctic region. He has also written a book, titled "The Arctic Man," published by Kodansha in 2013.

[Video] Panasonic LUMIX: Introducing Stories with GH5 - Polar Explorer Yasunaga Ogita
https://youtu.be/zZ0nVOlnEBE

Source and more photo: http://news.panasonic.com/global/topics/2018/54326.html

Related Links
LUMIX GH5 - Go Higher | Panasonic Global
https://www.panasonic.com/global/consumer/lumix/gh5/100th.html

LUMIX GH SERIES VIDEO & PHOTO GALLERY | Panasonic Global
https://www.panasonic.com/global/consumer/lumix/gh/gh5_video.html

LUMIX GLOBAL GATEWAY | Panasonic Global
https://www.panasonic.com/global/consumer/lumix/index.html

Polar Explorer Yasu Ogita Official Website
https://www.ogita-exp.com/english/

Beating the "Battle with Heat" for Even Greater Innovation in Professional Video Performance - LUMIX GH5 (Jul 11, 2017)
http://news.panasonic.com/global/stories/2017/48655.html

Panasonic and Digital Hollywood University Will Shoot and Live Stream YOHJI YAMAMOTO's Fashion Show at the Paris Collection (Feb 24, 2017)
http://news.panasonic.com/global/topics/2017/46121.html

[Press Release] Panasonic Develops the World's First 4K 60p/50p Video Recording Digital Single Lens Mirrorless Camera LUMIX GH5 Featuring '6K PHOTO' (Sep 20, 2016)
http://news.panasonic.com/global/press/data/2016/09/en160920-5/en160920-5.html

Contact information

Panasonic Corporation
Global Communications Department
Global PR Office
Click here to go to Media Contact form

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Philip Morris International and Dorna Switch Gears in Quest for a World without Tobacco Smoke17.11.2018 14:00Tiedote

Philip Morris International Inc. (PMI) (NYSE:PM) and Dorna Sports S.L., the commercial rights holder for the world FIM MotoGP Championships, have extended their partnership until the end of 2021. The two organizations have collaborated successfully for 26 years. As of 2019, the partnership will focus on advancing the cause of a smoke-free world. More than 1 billion people smoke today and, according to the World Health Organization, will continue to smoke in the near future. PMI has committed to transform its business and encourage all men and women who would otherwise continue smoking to replace cigarettes with better alternatives as soon as possible. With around 350 million MotoGP fans worldwide, MotoGP can play a significant role in positively impacting the lives of people who smoke and those around them. “The best choice for consumers concerned about the health risks of smoking is to quit tobacco and nicotine altogether. Today, however, technology, science and innovation provide a r

Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 21:00Tiedote

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)

Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 17:33Tiedote

Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W

Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 16:55Tiedote

Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 16:15Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk

Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 15:57Tiedote

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme